One Day MD | Evidence-Based Wellness

Scientific Review by the Clinical Editorial Team  |  Published: November 2019  |  Last Reviewed: July 2026   |  Category: Regenerative Medicine | Evidence Review Quick Answer Stem cell research has grown to over 379,000 published studies on PubMed as of mid-2026, but the evidence is not uniform across conditions. Hematopoietic stem cell transplantation for leukemia and lymphoma is decades-old, FDA-licensed standard of care. A donor islet cell therapy, Lantidra , became the first FDA-approved cellular therapy for type 1 diabetes in 2023, and a stem-cell-derived successor, zimislecel , is now in Phase 3 trials. Everything else on this page — stroke, osteoarthritis, spinal cord injury, autoimmune disease, heart disease, autism, anti-aging, hair loss, kidney and liver disease, and back pain — remains investigational, with no FDA-approved stem cell product for these indications. The FDA has repeatedly warned that clinics marketing unapproved st...

By Dr. Frank Yap, MD | Medically reviewed by One Day MD Review Team | Last updated: September 29, 2026 Quick Answer: One Day MD is an independent, evidence-based health library covering supplements, longevity, GLP-1 and weight management, cancer prevention, heart and metabolic health, brain and sleep, immunity, skin, joints, family health and finding a specialist. Use this page as your map: check the date, pick a pillar, then narrow by label. Disclosure: Some pages link to products or partners, and we may earn a commission at no cost to you. This is educational content, not medical advice. In This Guide How to Use This Site Topic Index (12 pillars) Site Tools and Sister Sites AI Personalization Guide FAQ How to Use This Site 1 Check the date : Look for the Last updated line. 2026 guides use current evidence; older posts may not. 2 Pick a pillar : Match your question to one of the 12 pillars below and read its flagship guides first. 3 Narrow by label : Labels list every post on ...

GLP-1 medications can produce substantial weight loss, but the scale does not tell you whether that weight came from fat, lean tissue, or both. As semaglutide, tirzepatide and other incretin-based therapies become increasingly important in obesity treatment, a more useful question is emerging: how can weight be lost while preserving muscle, physical function and long-term health? Evidence review updated: September 28, 2026  |  Topic: GLP-1 medications, muscle loss, lean mass, metabolism and weight regain The evidence in one paragraph: Substantial weight loss from semaglutide, tirzepatide and other incretin-based therapies can include a measurable reduction in lean mass. However, a 2026 systematic review and meta-analysis found that the proportion of total weight lost as lean mass was broadly comparable with intensive lifestyle-based weight loss, rather than showing that incretin drugs uniquely cause muscle loss. The same analysis found the most favorable lean-ma...